Timolol as a migraine acute attack therapy: randomized, OTCs control study

Abstract

Background: Migraine is manifested by recurrent headache attacks, with variable characteristics and associated symptoms. Oral beta blockers are widely used to prevent and reduce the frequency these attacks. However, the use of topical beta blockers for acute treatment is still controversial. Aims: In this randomized double – armed study, we aim to compare the efficacy of Timolol 0.5% eyedrops compared to other over-the-counter (OTC) medications used for acute treatment of migraine. Methods: Fifty-seven patients were randomly allocated to group A (treatment group: Timolol 0.5% eyedrops), and group B (control group: OTC drugs including Non-steroidal anti-inflammatory drugs (NSAIDs), caffeine, aspirin, and acetaminophen). The primary outcome was pain reduction. Secondary outcome measures included reducing nausea, vomiting, photophobia, and phonophobia. Results: Median pain reduction for the OTC group was higher than for timolol (6, 4 prospectively) with a significant U-test (p